Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling (2015)

  • Authors:
  • USP affiliated authors: ALVES, VENANCIO AVANCINI FERREIRA - FM ; SOARES, FERNANDO AUGUSTO - FO ; BELIZARIO, JOSE ERNESTO - ICB ; MALPARTIDA, HUMBERTO MIGUEL GARAY - EACH
  • USP Schools: FM; FO; ICB; EACH
  • DOI: 10.1186/s12885-015-1022-6
  • Subjects: MAMA; NEOPLASIAS; APOPTOSE; RATOS
  • Language: Inglês
  • Imprenta:
  • Source:
    • Título do periódico: BMC Cancer
    • ISSN: 1471-2407
    • Volume/Número/Paginação/Ano: v. 15, n. 70, p. (online), 2015
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1186/s12885-015-1022-6 (Fonte: oaDOI API)
    • Este periódico é de acesso aberto
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: gold
    • Licença: cc-by
    Versões disponíveis em Acesso Aberto do: 10.1186/s12885-015-1022-6 (Fonte: Unpaywall API)

    Título do periódico: BMC Cancer

    ISSN: 1471-2407

    • Melhor URL em Acesso Aberto:


    • Outras alternativas de URLs em Acesso Aberto:


        • Página do artigo
        • Evidência: oa journal (via doaj)
        • Licença: cc-by
        • Versão: publishedVersion
        • Tipo de hospedagem: publisher




        • Página do artigo
        • Link para o PDF
        • Evidência: oa repository (via OAI-PMH title and first author match)
        • Licença: cc-by
        • Versão: publishedVersion
        • Tipo de hospedagem: repository


        • Página do artigo
        • Link para o PDF
        • Evidência: oa repository (via OAI-PMH title and first author match)
        • Licença: cc-by
        • Versão: publishedVersion
        • Tipo de hospedagem: repository


        • Página do artigo
        • Evidência: oa repository (via pmcid lookup)
        • Licença:
        • Versão: publishedVersion
        • Tipo de hospedagem: repository


    Informações sobre o Citescore
  • Título: BMC Cancer

    ISSN: 1471-2407

    Citescore - 2017: 3.49

    SJR - 2017: 1.464

    SNIP - 2017: 1.066


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2686412-10BCSEP 163 2015
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BANCOVIK, Jasna; MOREIRA, Dayson F.; CARRASCO, Daniel; et al. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling. BMC Cancer, Londres, v. 15, n. 70, p. (online), 2015. Disponível em: < http://www.biomedcentral.com/1471-2407/15/70 > DOI: 10.1186/s12885-015-1022-6.
    • APA

      Bancovik, J., Moreira, D. F., Carrasco, D., Yao, J., Porter, D., Moura, R., et al. (2015). Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling. BMC Cancer, 15( 70), (online). doi:10.1186/s12885-015-1022-6
    • NLM

      Bancovik J, Moreira DF, Carrasco D, Yao J, Porter D, Moura R, Camargo A, Fontes-Oliveira CC, Garay-Malpartida MH, Carambula S, Vannier E, Strauss BE, Wakamatsu A, Alves VAF, Logullo AF, Soares FA, Polyak K, Belizário JE. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling [Internet]. BMC Cancer. 2015 ; 15( 70): (online).Available from: http://www.biomedcentral.com/1471-2407/15/70
    • Vancouver

      Bancovik J, Moreira DF, Carrasco D, Yao J, Porter D, Moura R, Camargo A, Fontes-Oliveira CC, Garay-Malpartida MH, Carambula S, Vannier E, Strauss BE, Wakamatsu A, Alves VAF, Logullo AF, Soares FA, Polyak K, Belizário JE. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling [Internet]. BMC Cancer. 2015 ; 15( 70): (online).Available from: http://www.biomedcentral.com/1471-2407/15/70

    Referências citadas na obra
    Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domenici J, et al. A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A. 2003;100:10931–6.
    Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol. 2001;2:1133–7.
    Rieg S, Garbe C, Sauer B, Kalbacher H, Schittek B. Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol. 2004;151:534–9.
    Minami Y, Uede K, Furukawa F, Sagawa K, Kimura A, Tsuji T. Cutaneous mixed tumors: an immunohistochemical study using two antibodies, G-81 and C8/144B. J Dermatol Sci. 2004;36:180–2.
    Minami Y, Uede K, Sagawa K, Kimura A, Tsuji T, Furukawa F. Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidin. Br J Dermatol. 2004;151:165–9.
    Stewart GD, Lowrie AG, Riddick AC, Fearon KC, Habib FK, Ross JA. Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. Prostate. 2007;67:1308–17.
    Stewart GD, Skipworth RJ, Pennington CJ, Ross JA, Fearon KCH, Baracos VE. Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. Br J Cancer. 2008;99:126–32.
    Stewart GD, Skipworth RJ, Ross JA, Fearon K, Baracos VE. The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. Curr Opin Clin Nutr Metab Care. 2008;11:208–13.
    Lowrie AG, Wigmore SJ, Wright DJ, Waddell ID, Ross JA. Dermcidin expression in hepatic cells improves survival without N-glycosylation, but requires asparagine residues. Br J Cancer. 2006;94:1663–71.
    Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M. Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol. 2002;177:32–9.
    Cunningham TJ, Hodge L, Speicher D, et al. Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. J Neurosci. 1998;18:7047–60.
    Rieg S, Seeber S, Steffen H, Humeny A, Kalbacher H, Stevanovic S, et al. Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. J Invest Dermatol. 2006;126:354–65.
    Steffen H, Rieg S, Wiedemann I, Kalbacher H, Eeg M, Sahl HG, et al. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother. 2006;50:2608–20.
    Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg. 2000;87:53–8.
    Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer. 1999;80:1734–7.
    Lee Motoyama JP, Kim-Motoyama H, Kim P, Nakagama H, Miyagawa K, Suzuki K. Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity. Biochem Biophys Res Commun. 2007;357:828–33.
    Sanghi S, Kumar R, Lumsden A, Dickinson D, Klepeis V, Trinkaus-Randall V, et al. cDna and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland. J Mol Biol. 2001;310:127–39.
    Ma P, Beck SL, Raab RW, McKown RL, Coffman GL, Utani A, et al. Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J Cell Biol. 2006;174:1097–106.
    Wang J, Wang N, Xie J, McKown RL, Raab RW, Ma P, et al. Restricted epithelial proliferation by lacritin via PKC alpha-dependent NFAT and mTOR pathways. J Cell Biol. 2006;174:689–700.
    Weigelt B, Bosma AJ, Van’t Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. J Cancer Res Clin Oncol. 2003;129:735–6.
    Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13:394–406.
    Majczak G, Lilla S, Garay-Malpartida M, Marcovik J, Medrano FJ, de Nucci G, et al. Prediction and biochemical characterization of intrinsic disorder in the structure of proteolysis-inducing factor/dermcidin. Genet Mol Res. 2007;6:1000–11.
    Li C, Wong WH. DNA-Chip Analyzer (dChip). In: Parmigiani G, Garrett ES, Irizarry R, Zeger SL, editors. The analysis of gene expression data: methods and software. New York: Springer; 2003. p. 120–41.
    Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008;68:9532–40.
    Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36.
    Sagawa K, Kimura A, Saito Y, Inoue H, Yasuda S, Nosaka M, et al. Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification. Int J Legal Med. 2003;117:90–5.
    Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-2-overexpressing breast cancer cells. Clin Cancer Res. 2003;9:1274–83.
    Logullo AF, Stiepcich MMA, Osório CABP, Nonogaki S, Pasini FS, Rocha RM, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011;58:617–25.
    Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27.
    Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol. 2007;7:392–7.
    Muraoka-Cook RS, Feng SM, Strunk KE, Earp 3rd HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia. 2008;13:235–46.
    Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp 3rd HS. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol Endocrinol. 2008;22:2307–3021.
    Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:4217–25.
    Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 2008;19:73–80.
    Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505–16.
    Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis inducing factor and its role in cancer cachexia. Clin Cancer Res. 2004;10:5862–9.
    Song C, Weichbrodt C, Salnikov ES, Dynowski M, Forsberg BO, Bechinger B, et al. Crystal structure and functional mechanism of a human antimicrobial membrane channel. Proc Natl Acad Sci U S A. 2013;110(12):4586–91.
    Moreira DF, Strauss B, Vannier E, Belizário JE. Genes up and down regulated by dermcidin in breast cancer: a microarray analysis. Genet Mol Res. 2007;7(4):925–32.
    Ritter CA, Perez-Torrres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909–19.
    Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582–7.